Immunoprecise Antibodies Ltd. (IPA) has developed a new class of GLP-1 therapies entirely through AI, designed to enhance efficacy, safety, therapy longevity and patient satisfaction for the treatment of diabetes.
A paracrine hormone of skeletal muscle acts as an endocrine signal for the synthesis of a sex hormone. Scientists at McGill University have observed in mice how myostatin, which inhibits the development of muscle mass to control its growth, also stimulated the production of the pituitary follicle-stimulating hormone (FSH), modulating ovarian function. The hypothalamus-pituitary-gonadal axis could include an additional element through a yet unknown role in muscles.
The largest analysis to date of patients taking GLP-1 receptor agonists (GLP-1RAs) has investigated their effects on nearly 175 diseases, and found that compared to three other classes of diabetes medications, individuals with a prescription for GLP-1RAs had a reduced risk of 42 diseases, and an increased risk of 19. The findings, which were published Jan. 20, 2025, in Nature Medicine, provide a comprehensive overview of GLP-1RAs’ effects.
A global commission has proposed a fundamental change to the way obesity is defined and diagnosed. If the change is implemented, obesity would be considered a health risk in some contexts, and a disease in others. “The commission is reframing obesity... in a way that allows for the nuanced reality of obesity,” Robert Eckel told reporters at a press briefing announcing the proposal, which was published online in The Lancet Diabetes & Endocrinology on Jan. 14, 2025.
Canary Cure Therapeutics (Canary Global Inc.) has released preclinical results for its lead candidate, CCT-217, an siRNA therapeutic targeting cannabinoid CB1 receptor (CB1R) and zinc finger protein 423 (ZFP423) to treat obesity.
Alesta Therapeutics BV has closed an oversubscribed €65 million (US$67 million) series A financing round designed to support development of its two small-molecule therapeutics.
Sun Pharmaceutical Industries Ltd. has divulged incretin analogues acting as dual agonists of gastric inhibitory polypeptide (GIPR) receptor/GLP-1 or GLP-1/glucagon receptor (GCGR) or triple agonists of GIPR/GLP-1/GCGR reported to be useful for the treatment of type 2 diabetes, dyslipidemia, obesity, metabolic syndrome, neurodegeneration, fibrosis and cardiovascular disorders.
Ibio Inc. has expanded its cardiometabolic and obesity treatment development program by in-licensing a long-acting anti-myostatin antibody from Astralbio Inc. The antibody, now named IBIO-600, was identified by Astralbio using Ibio’s proprietary technology stack.